Welcome to our dedicated page for Progyny news (Ticker: PGNY), a resource for investors and traders seeking the latest updates and insights on Progyny stock.
Progyny, Inc. (Nasdaq: PGNY) is a leading fertility and family building benefits company that integrates service, science, technology, and data to provide comprehensive fertility solutions for self-insured employers. The company's unique approach offers members tailored, value-based treatment plans, leveraging the latest medical advancements to improve outcomes, shorten the time to pregnancy, and reduce fertility-related costs.
Progyny's benefit plans encompass a wide range of fertility solutions, including IVF (In Vitro Fertilization), IUI (Intrauterine Insemination), embryo banking, egg freezing, adoption, and surrogacy. These plans are supported by Progyny's network of high-quality fertility specialists, known for their expertise in performing Smart Cycle treatments.
Headquartered in New York City, Progyny has established itself as a transformative leader in the fertility benefits space, partnering with employers across various industries. The company's clients benefit from a premier network of fertility and women's health specialists, advanced clinical outcomes, and reduced healthcare costs.
Progyny has been recognized for its leadership and growth, earning accolades from CNBC Disruptor 50, Modern Healthcare’s Best Places to Work in Healthcare, Forbes’ Best Employers, Financial Times, Inc. 5000, Inc. Power Partners, and Crain’s Fast 50 for NYC.
In the third quarter of 2023, Progyny reported having 392 clients, a significant increase from 282 clients in the same period in 2022. The company's financial performance includes positive Adjusted EBITDA, demonstrating robust profitability and financial health. Progyny continues to expand its services and partnerships, ensuring comprehensive support for patients and employers alike.
For more information, visit www.progyny.com. Investors can reach out to James Hart at investors@progyny.com, and media inquiries can be directed to Selena Yang at media@progyny.com.
Progyny, Inc. (Nasdaq: PGNY) will report its financial results for the quarter ending March 31, 2023, on May 8, 2023, after market close. The company will host a conference call at 4:45 PM ET to discuss these results. Interested participants can access the call by dialing specific numbers provided for U.S. and international participants using the passcode 265484. An audio replay will be available until May 15, 2023. Progyny specializes in fertility benefits management, offering comprehensive solutions that include education, access to specialists, and cost reduction for employers. The company has received recognition from several reputable organizations for its growth and leadership in the healthcare sector.
Progyny, Inc. (Nasdaq: PGNY), a leader in fertility benefits management, is partnering with RESOLVE: The National Infertility Association to raise awareness during National Infertility Awareness Week 2023. This includes lighting the Empire State Building in orange and ringing the Nasdaq Closing Bell on April 25, 2023. The CDC reports that 1 in 5 married women in the U.S. face infertility issues, highlighting the struggles many endure to build families. Progyny’s CEO, Pete Anevski, emphasizes the company’s commitment to supporting individuals facing infertility, with successful outcomes for tens of thousands so far. The ceremony aims to amplify this message, reaching audiences beyond New York City. Celebrities like Adrienne Bailon-Houghton are also involved, advocating for increased access to family building care. This collaboration reflects a significant step in addressing infertility stigma.
Progyny, Inc. (Nasdaq: PGNY) recently appointed Dr. Janet Choi as Chief Medical Officer, leveraging over 20 years of experience in reproductive health. Formerly the Medical Director at CCRM New York, Dr. Choi will advance the company’s clinical strategy in family building benefits. Her leadership aims to enhance quality and effectiveness in care, emphasizing the importance of inclusive employer-sponsored benefits. Dr. Choi is a recognized expert, having been featured in New York Magazine’s Top Doctors and Castle Connolly’s 'Top Doctors.' This strategic addition signals Progyny's commitment to pioneering solutions in women's health and fertility benefits.
Progyny, Inc. (Nasdaq: PGNY) has announced a partnership with the Children's Hospital Association (CHA), serving over 220 children’s hospitals. This collaboration positions Progyny as CHA's preferred provider for fertility and family building benefits, emphasizing clinical outcomes and cost efficiency. The partnership allows member hospitals to engage directly with Progyny for customizable plans that support healthcare professionals and their families. Progyny aims to enhance recruitment and retention in hospitals by offering access to over 950 top fertility specialists and dedicated fertility coaching.
FAQ
What is the current stock price of Progyny (PGNY)?
What is the market cap of Progyny (PGNY)?
What services does Progyny offer?
Who are Progyny's clients?
How does Progyny's approach improve fertility outcomes?
What recognition has Progyny received?
Where is Progyny headquartered?
How many clients did Progyny have in the third quarter of 2023?
What are the financial highlights of Progyny for the third quarter of 2023?
How can investors and media contact Progyny?
What is the Smart Cycle treatment?
What makes Progyny's benefits solution unique?
